

References

Section I. Cardiovascular disease: Growing causes for concern

1. American Heart Association. *2001 Heart and Stroke Statistical Update*.
2. National Institutes of Health. National Heart Lung and Blood Institute. *Morbidity and Mortality 1998 Chartbook on Cardiovascular, Lung and Blood Diseases*.
3. Mokdad AH, Ford ES, Bowsman B, et al. Diabetes trends in the US: 1990-1998. *Diabetes Care*. 2000;23:1278-1283.
4. The Lancet. The hidden epidemic of cardiovascular disease. *Lancet*. 1998;352:1795.
5. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020. Burden of Disease Study. *Lancet*. 1998;349:1498-1504.
6. Napoli C, D'Armiento FP, Mancini FP, Postiglione A, Witztum JL, Palumbo G, Palinski W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. *J Clin Invest*. 1997;100:2680-2690.
7. Napoli C, Glass CK, Witztum JL, Deutsch R, D'Armiento FP, Palinski W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. *Lancet*. 1999;354:1234-1241.

Section II. The vasculature: Insights into new pathways and targets for treatment

1. Gibbons G, Dzau VJ. The emerging concepts of vascular remodeling. *N Engl J Med*. 1994;330:1431-1438.
2. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. *Am J Med*. 1998;105(1A):32S-39S.
3. Pepine CJ. The effects of antiangiotensin-converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial infarction. *Am J Cardiol*. 1998;82(10A):23S-27S.
4. Stary HD, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Report from the Committee of Vascular Lesions of the Council of Atherosclerosis. American Heart Association. *Circulation*. 1995;92:1355-1374.
5. Britten MD, Seiher AM, Schachinger V. Clinical importance of endothelial function in the human coronary and peripheral circulation. *J Intern Med*. 1999;245:315-327.
6. Panza JA, Quyyumi AA, Callahan TS, Epstein S. Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. *J Am Coll Cardiol*. 1993;21:1145-1151.
7. Taddei S, Virdis A, Mattei P, Arzilli F, Salvetti A. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with a familial history of hypertension. *J Cardiovasc Pharmacol*. 1992;20(suppl 12):S193-S195.
8. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. *Circulation*. 1993;88:2510-2516.
9. Hashimoto M, Eto M, Akishita M, Kozaki K, Ako J, Iijima K, Kim S, Toba K, Yoshizumi M, Ouchi Y. Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. *Arterioscler Thromb Vasc Biol*. 1999;19:2795-2800.
10. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. *Circulation*. 2000;101:948-954.

11. Neunteufl T, Heher S, Katzenschlager R, Wolf G, Kostner K, Maurer G, Weidinger F. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. *Am J Cardiol.* 2000;86:207-210.
12. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, Matsuura H, Kajiyama G, Oshima T. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. *J Am Coll Cardiol.* 2000;35:284-291.

Section III. The renin-angiotensin system and ACE inhibition

1. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy. *Arch Intern Med.* 1993;153:937-942.
2. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. *Eur Heart J.* 1998;19(suppl J):J2-J6.
3. Weir MR, Dzau JV. The renin-angiotensin-aldosterone system: A specific target for hypertension management. *Am J Hypertens.* 1999;12:205S-213S.
4. Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M, Tanouchi J, Yamada Y, Kamada T. Increased Angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. *Circulation.* 2001;103:630-633.
5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. *Circulation.* 1998;97:1411-1420.
6. Dzau VJ, Pratt R, Gibbons GH. Angiotensin as a local modulating factor in ventricular dysfunction and failure due to coronary disease. *Drugs.* 1994;47(suppl 4):1-13.
7. Hamsten A, Wiman G, De faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor activity in young survivors of myocardial infarction. *N Engl J Med.* 1985;313:1557-1563.
8. Vaughan DE, Rouleau J-L, Ridker PM, Arnold MO, Menapace FJ, Pfeffer MA, on behalf of the HEART study investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. *Circulation.* 1997;96:442-447.
9. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. *Annu Rev Cell Biol.* 1988;4:93-126.
10. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischemic heart disease in the Northwick park Heart study. *Lancet.* 1993;342:1076-1079.
11. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. *Circulation.* 2000;101:264-269.
12. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetics compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. *Circulation.* 1998;97:2213-2221.
13. Wright RA, Flapan AD, Alberti KGMM, Ludlam CA, Fox KAA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. *J Am Coll Cardiol.* 1994;24:67-73.
14. Moriyama Y, Ogawa H, Oshima S, Takazoe K, Honda Y, Hirashima O, Arai H, Sakamoto T, Sumida H, Suefuji H, Kaikita K, Yasue H. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. *Jpn Cir J.* 1997;61:308-314.

Section IV. Interactions of the RAS and lipids

1. Lloyd-Jones DM, Evans JC, Larson MG, O'Connell CJ, Wilson PWF, Levy D. Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. *Arch Intern Med.* 1999;159:2206-2212.
2. Sung BH, Izzo JL, Wilson MF. Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. *Am J Hypertens.* 1997;10:592-599.
3. Morawietz H, Rueckschloss U, Niemann B, Duerschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. *Circulation.* 1999;100:899-902.
4. Miyazaki M, Sakonjo H, Takai S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. *Br J Pharmacol.* 1999 Oct;128(3):523-529.
5. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT₁ receptor function and density in hypercholesterolemic men. *Circulation.* 1999;100:2131-2134.
6. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. *Hypertension.* 1999;33:719-725.

Section V. Improving outcomes in CAD: Trial updates

1. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. *Circulation.* 1994;90:2056-2069.
2. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. *Lancet.* 1995;345:669-685.
3. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Wertheimer JH, Hawkins CM, on behalf of the SAVE investigators. Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. *N Engl J Med.* 1992;327:669-677.
4. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H, on behalf of the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). *N Engl J Med.* 1992;327:678-684.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med.* 1991;325:293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med.* 1992;327:685-691.
7. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarcto miocardico. GISSI-3: effects of lisinopril and transdermyl glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. *Lancet.* 1994;343:1115-1122.
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet.* 1993;342:821-828.

9. Køber L, Topr-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, Videbek J, Cole DS, Auclert L, Pauly NC, Aliot E, Pedersen S, Camm A, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med*. 1995;333:1670-1676.
10. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342:145-153.
11. Cashin-Hemphill L, Holmvang G, Chan RC, et al, for the QUIET investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. *Am J Cardiol*. 1999;83:43-47.
12. Pfeffer MA, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J, Braunwald E. Prevention of Events with Angiotensin Converting Enzyme Inhibition (the PEACE study design). *Am J Cardiol*. 1998;82:25H-30H.
13. Fox KM, Henderson JR, Bertrand MD, Ferrari R, Remme WJ, Simoon ML. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease. *Eur Heart J*. 1998;19(suppl J):J52-J55.
14. The Heart Outcome Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE substudy. *Lancet*. 2000;355(9200):253-259.
15. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. *N Engl J Med*. 1998;338:645-652.
16. Tatti P, Guarisco R, Pahor M, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care*. 1998;21:597-603.
17. Hansson L, Lindholm LH, Niskanen L, Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. *Lancet*. 1999;353:611-616.
18. Neil B, MacMahon S. The PROGRESS study: rationale and design. *J Hypertens*. 1995;13:1869-1873.
19. Oosterga M, Voors AA, Pinto VM, Buikema H, Grandjean JG, Kigma JH, Crijns HJGM, van Gilst WH. Effects of quinapril on clinical outcome after coronary bypass grafting (The QUO VADIS study). *J Am Coll Cardiol*. 2001;37:542-546.
20. Kjølner-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post-Revascularization Study (APRES). *J Am Coll Cardiol*. 2000;35:881-888.
21. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. *Circulation*. 1998;97:2202-2212.
22. Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace FJ, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The Healing and Early Afterload Reducing Therapy Trial. *Circulation*. 1997;95:2643-2651.
23. Aikawa Y, Rohde L, Plehn J, Greaves SC, Menapace F, Arnold JMO, Rouleau J-L, Pfeffer MA, Lee RT, Solomon SD. Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Therapy Trial (HEART): An echocardiography-based structural analysis. *Am Heart J*. 2001;141:234-242.

24. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, Frederick PD, Every N. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. *J Am Coll Cardiol*. 2000;36:2056-2063.
25. Yusuf S. Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) study. *European Heart Journal*. 2001;22:103-104.
26. Lonn WM, Yusuf S, Doris CI, Sabine J, Dzavik V, Hutchison K, Riley WA, Tucker J, Pogue J, Taylor W, for the SECURE Investigators. Study design and baseline characteristics of the study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E: SECURE. *Am J Cardiol*. 1996;8:914-919.
27. Lonn EM, Yusuf S, Dzavik V, Doris I, Qilong Y, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK, for the SECURE investigators. Effects of ramipril and Vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). *Circulation*. 2001;103:919-925.
28. Cashin-Hemphill L, Dinsmore RE, Chan RC, William SN, Holmvang G, Haber HE, Lees RS for the QUIET investigators. LDL-cholesterol and angiographic progression in the QUIET trial (abstract) *J Am Coll Cardiol*. 1997;29(suppl A):85A. Abstract 725-1.
29. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/enalapril Coronary Atherosclerosis Trial. *Circulation*. 2000;102:1748-1754.
30. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. *J Am Coll Cardiol*. 2000;36:438-443.
31. Hosomi K, Mizushige K, Ohyama H, Hatanaka Y, Matsuo H, Koziol J. ACE inhibition with enalapril slows progressive intima-media thickening of common carotid artery in NIDDM patients [Abstract]. *Circulation*. 2000;102(suppl II):II-869.
32. Lonn EM, Shaishkoleslaami R, Y; Q, Bosch J, Magi A, Yusuf S. Effect of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. Presented at American College of Cardiology 50th Annual Scientific Session; March 18-21, 2001; Orlando, FL.
33. O'Keefe JH, Wetzel M, Moe RR, Brosnahan K, Lavie CH. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? *J Am Coll Cardiol*. 2001;37:1-8.
34. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. *Circulation*. 1998;97:1411-1420.
35. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. *Clin Pharmacokinet*. 1994;26:7-15.
36. Unger T, Ganten D, Lang RE. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: Therapeutic implications. *Am J Cardiol*. 1987;59:18D-22D.
37. Erman A, Winkler J, Chen-Gal B, Rabinov M, Zelykovski A, Tadjer S, Shmeuli J, Levi E, Akbary A, Rosenfeld JB. *J Hypertension*. 1991;1057-1062.
38. Waugh WJ. Factors to consider in selecting an angiotensin-converting enzyme inhibitor. *Am J Health-Syst Pharm*. 2000;57(suppl 1):S26-S30.
39. Henney JE. From the Food and Drug Administration: Preventive use for ramipril. *JAMA*. 2000;284:2711.

40. Furberg CD. Class effects and evidence-based medicine. *Clinical Cardiology*. 2000;23(suppl IV):15-19.
41. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL Jr. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. *Am J Cardiol*. 1998;82:465-469
42. Stern N, Grosskopf I, Shapira I, Kisch E, Isaacov A, Limor R, Baz M, Leshem Y, Flatau E, Miller A, Greenman Y. Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. *J Intern Med*. 2000;248:203-210.
43. Castelli WP. Epidemiology of Coronary Heart Disease. The Framingham Study. *Am J Med*. 1984; 76:4-12
44. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. *Stroke*. 1991;22:312-318.
45. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med*. 1997;157:2413-2446.
46. Sowers JR, Reed J. 1999 Clinical Advisory Treatment of Hypertension and Diabetes. *J Clin Hypertens*. 2000;2:132-133.
47. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. (ALLHAT). *JAMA*. 2000;283:1967-1975.
48. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. *Hypertension*. 2000;35:1021-1024.
49. Hansson L, Lindholm LH, Ekblom T, Dahlöf B, Lanke J, Scherstein B, Webster P-O, Hedner T, deFaiare U, for the STOP-Hypertension-2 Study Group. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet*. 1999;354:1751-1756.
50. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. *BMJ*. 1998;317:703-713.
51. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. *Lancet*. 1998;352:837-853.
52. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. *Lancet*. 1998;351:1755-1762.
53. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. *Diabetes Care*. 2001;24(suppl 1):S33-S43.
54. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hseuh W, Sowers J for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. *Am J Kidney Dis*. 2000;36:646-661.
55. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas MC, Paranandi L, Peterson JC, Porash JG, Rauch S, Soucie JM, Stollar C. Achievement and safety of a low BP goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension*. 1997;641-650.

56. Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel J-P, Coope J, Ekblom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. *Lancet*. 2000;355:865-872.
57. American Heart Association year-end report, December 28, 2000.
58. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, de Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. *Circulation*. 2001;103:163-182.
59. Bosch J, Yusuf S, Pogue J, Probstfield J, Diaz R, Hoeschen R, Ostergren J on behalf of the HOPE investigators. Impact of ramipril and vitamin E on cerebrovascular events in the HOPE trial. *J Am Coll Cardiol*. 2000;35(suppl A):324A.
60. Sacks FM, Pfeffer MA, Moye LA, Rouleau J-L, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JWO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *N Engl J Med*. 1996;335:1001-1009.
61. The LIPID Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. *N Engl J Med*. 1998;339:1349-1357.
62. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Seiher A, Chaitman B, Leslie S, Stern S, for the MIRACL Investigators. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Trial: Effects of intensive atorvastatin treatment with early recurrent events after an acute coronary syndrome. *Circulation*. 2000;102:2672.
63. Ross SD, Allen IE, Connelly JE, Korenblatt BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials. A meta-analysis. *Arch Intern Med*. 1999;159:1793-1802.
64. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. *JAMA*. 1998;280:1930-1935.
65. United States Renal Data Service. *USRDS 1999 Annual Data Report*. Bethesda, Md. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1999.
66. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, Paranandi L, Peterson JC, Porush JG, Rauch S, Soucie JM, Stollar C. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. *Hypertension*. 1997;29:641-650.
67. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. *Arterioscler Thromb Vasc Biol*. 1999;19:1992-1997.
68. The HOPE study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. *Lancet*. 2000;355:253-259.
69. Mann JF, Gerstein HC, Pogue JM, Bosch JJ, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: the HOPE study. *Circulation*. 2000;102(suppl II):II-655. Abstract 3180.
70. GISEN (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. *Lancet*. 1997;349:1857-1863.

71. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet*. 1999;354:359-364.
72. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G, on behalf of the Gruppo Italiano di Studi Epidemiologici in Nefrologia. Renal function and requirement in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. *Lancet*. 1998;352:1252-1256.
73. Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G. Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. *Kidney International*. 2001;59:286-294.

Section VI. Lipids: New insights into the importance of aggressive treatment

1. Rauch U, Osende JI, Chesebro JH, Fuster V, Vorchheimer DA, Harris K, Harris P, Sandler DA, Fallon JT, Jayaraman S, Badimon JJ. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. *Atherosclerosis*. 153:181-189.
2. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. *Am J Cardiol*. 1997 Feb 1;79(3):350-354.
3. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. *Circulation*. 1997;95:76-82.
4. Shechter M, Sharir M, Labrador MJ, Forrester J, Merz CN. Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels <100 mg/dl. *Am J Cardiol*. 2000;86:1256-1259.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). *JAMA*. 1993;269:3015-3023.
6. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin J-L, Monjaud I, Guisoillet J, Touboul P, Delaye J. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of heart disease. *Lancet*. 1994;343:1454-1459.
7. de Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P, Delaye J. Effect of a mediterranean type of diet on the rate of cardiovascular complications in patients with coronary artery disease. Insights into the cardioprotective effect of certain nutrients. *J Am Coll Cardiol*. 1996;28:1103-1108.
8. Vogel RA, Corretti MC, Plotnick GD. The postprandial effect of components of the Mediterranean diet on endothelial function. *J Am Coll Cardiol*. 2000;36:1455-1460.
9. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation*. 1999;99:779-785.
10. Vergnani L, Hatik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovich V, Fellin R, Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. *Circulation*. 2000;101:1261-1266.
11. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. *Circulation*. 1995;92:3172-3177.
12. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. *Arterioscler Thromb Vasc Biol*. 2000;20:556-562.

13. Palinski W. Immunomodulation: A new role for statins? *Nature Med.* 2000;6:1311-1312.
14. Faggiotto A, Paoletti R. State of the art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. *Hypertension.* 1999;34:987-996.
15. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. *Nat Med.* 2000;6:1399-1402.
16. Lansky AH, Popma JJ, Mintz GS, Laird JR, Saucedo JF, Leon MB. Lipid-lowering therapy after coronary revascularization: the interventional cardiologist's perspective. *Am J Cardiol.* 1998;81(7A):55E-62E.
17. RITA-2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomized Intervention Treatment of Angina (RITA-2) trial. *Lancet.* 1997;350:461-468.
18. Kullo IJ, Edwards WD, Schwartz RS. Vulnerable plaque: pathobiology and clinical implication. *Ann Intern Med.* 1998;18:1885-1894.
19. Forrester JS, Shah PK. Lipid lowering versus revascularization: an idea whose time (for testing) has come. *Circulation.* 1997;96:1360-1362.
20. Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CR. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. *Circulation.* 1997;95:2037-2043.
21. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. *Am J Cardiol.* 1998;82(suppl):3Q-12Q.
22. Riegger G, Abletshausen C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, Welzel D. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. *Atherosclerosis.* 1999;144:263-270.
23. Topol EJ, Serruys PW. Frontiers in interventional cardiology. *Circulation.* 1998;98:1802-1820.
24. Edelman ER, Rogers C. Pathobiologic responses to stenting. *Am J Cardiol.* 1998;81(7A):4E-6E.
25. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. *N Engl J Med.* 1997;80:1130-1133.
26. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. *Circulation.* 1998;98:851-855.
27. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. *Arch Intern Med.* 2000; 60:459-467.
28. Bramlet DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. *Am J Cardiol.* 1997 Oct 30;80(8B):39H-44H.
29. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *N Engl J Med.* 1997;336:153-162.

30. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. *N Engl J Med.* 1995 Nov 16;333(20):1301-1307.
31. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA.* 1998;279:1615-1622.
32. 4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet.* 1994 Nov 19; 344(8934):1383-1389.
33. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996;335:1001-1009.
34. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med.* 1998;339:1349-1357.
35. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin Versus Revascularization Treatment Investigators. *N Engl J Med.* 1999;341:70-76.
36. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. *Am J Cardiol.* 1998;82(suppl):3Q-12Q.
37. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). *Am J Cardiol.* 1998;81:582-587.
38. Smilde TJ, van Wissen S, Wollershein H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia: ASAP: a prospective, randomized double-blind trial. *Lancet.* 2001;357:577-581.
39. The LIPID Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. *N Engl J Med.* 1998;339:1349-1357.
40. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. *Am J Cardiol.* 1998;81:578-581.
41. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman B, Leslie S, Stern T. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. *JAMA.* 2001;285:1711-1718.
42. Arntz H-R, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, Schultheiss HP. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). *Am J Cardiol.* 2000;86:1293-1298.

43. Liem A, van Boven AJ, Withagen AP, Robles de Mecina RM, Veeger NJGM, Tissen JGP. Fluvastatin in acute myocardial infarction. Effects on early and late ischemia and events: the FLORIDA trial. Presented at the American Heart Association Scientific Session 2000, November 15, 2000, New Orleans, La.
44. Aronow HD, Houghtaling PL, Wolski KE, Topol EJ, Lauer MS. Stunning reduction in death and myocardial infarction observed with early lipid lowering after acute coronary syndromes. *J Am Coll Cardiol.* 2001;37(suppl A):334A.
45. Stenestrand U, Wallentin L for the Swedish Registry of Cardiac Intensive Care. Early statin treatment following acute myocardial infarction and 1-year survival. *JAMA.* 2001;285:430-436.
46. Muhlestein JB, Horne BD, Bair T, Li Q, Madsen TE, Pearson RR, Anderson JL. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. *Am J Cardiol.* 2001;87:257-261.
47. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. *Circulation.* 2001;103:38-44.

Section VII: Diabetes and the impact of risk factor clustering on CV risk

1. National Diabetes Data Group. *Diabetes in America.* 2nd Ed. NIH. 1995.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Maakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med.* 1998;339:229-234.
3. Wilson PWF, Kannel WB. In: Ruderman N, et al, eds. *Hyperglycemia, Diabetes and Vascular Disease.* Oxford: 1992.
4. Sowers JR. Diabetes mellitus and cardiovascular disease in women. *Arch Intern Med.* 1998;158:617-621.
5. Fagan TC, Deedwania PC. The cardiovascular dysmetabolic syndrome. *Am J Med.* 1998;105(1A):77S-82S.
6. Mannami T, Baba S, Ogata J. Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city: the Suita Study. *Arch Intern Med.* 2000;160:2297-2303.
7. Byberg L, Siegbahn A, Berglund L, McKeigue P, Reneland R, Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. *Arterioscler Thromb Vasc Biol.* 1998;18:258-264.
8. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care.* 1993;16:434-444.
9. Jamerson SA. Treating high-risk hypertensive patients. *Am J Hypertens.* 2000 May;13(5 Pt 2):68S-73S.
10. Sprecher DL, Pearce GL. How deadly is the "deadly quartet"? A post-CABG evaluation. *J Am Coll Cardiol.* 2000;36:1159-1165.
11. American Diabetes Association. Clinical practice recommendations 2001: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care.* 2001;24(suppl 1):S5-S20.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet.* 2000;355(9200):253-259.

13. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med.* 2000;342:145-153.
14. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahllof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet.* 1999;353(9153):611-616.
15. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. *Circulation.* 1997;96:4239-4245.
16. American Diabetes Association. Clinical practice recommendations 2001: Standards of medical care for patients with diabetes mellitus. *Diabetes Care.* 2001;24(suppl 1):S33-S43.
17. American Diabetes Association. Clinical practice recommendations 2001: Management of dyslipidemia in adults with diabetes. *Diabetes Care.* 2001;24(suppl 1):S58-S61.
18. Aguilar-Salinas CA, Gomez-Perez FJ, Posadas-Romero C, Vazquez-Chavez C, Meaney E, Gullias-Herrero A, Guillen LE, Alvarado Vega A, Mendoza Perez E, Eduardo Romero-Nava L, Angelica Gomez-Diaz R, Salinas-Orozco S, Moguel R, Novoa G. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. *Atherosclerosis.* 2000;152:489-496.
19. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). *Diabetes Care.* 1997 Apr;20(4):614-620.
20. Tikkanen MJ, Laakso M, Ilmonen M, Helve E, Kaarsalo E, Kilkki E, Salveto J. Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. *Diabetes Care.* 1998;21:477-481.
21. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med.* 1996;335:1001-1009.
22. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. *Circulation.* 1998;98:2513-2519.
23. Steiner G. Lipid intervention trials in diabetes. *Diabetes Care.* 2000;23(suppl 2):B49-B53.
24. Buse JB. Progressive use of medical therapies in type 2 diabetes. *Diabetes Spectrum.* 2000;13:211-220.
25. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *Arch Intern Med.* 1997;157:2413-2446.
26. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. *Hypertension.* 2000;35:1021-1024.
27. National Cholesterol Education Program (NCEP) Expert Panel: Summary of the second report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol. *JAMA.* 1993;209:3015-3023.
28. American Diabetes Association. Clinical practice recommendations 2001. *Diabetes Care.* 2001(suppl 1):1-133.

29. Grover SA, Coupal L, Zowall H, Alexander CM, Weiss TW, Gomes DR. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? *Diabetes Care*. 2001;24:45-50.

Section VIII: Heart failure: The RAS as the key to prevention and treatment

1. Wilson PWF. An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. *Am J Cardiol*. 1998;80(11a):2L-6L.
2. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure: a clinical mechanistic overview. *Arch Intern Med*. 1996;156:1789-1796.
3. Krum H. New and emerging pharmacologic strategies in the management of chronic heart failure. *Clin Cardiol*. 2000;23:724-730.
4. Davies MK, Gibbs CR, Lip GYH. ABC of heart failure management: Diuretics, ACE inhibitors, and nitrates. *BMJ*. 2000;320:428-431.
5. Davies MK, Gibbs CR, Lip GYH. ABC of heart failure management: digoxin and other inotropes, beta blockers, and antiarrhythmic and antithrombotic treatment. *BMJ*. 2000;320(7233):495-498.
6. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. *Lancet*. 2000;355(9215):1575-1581.
7. Garg G, Yusuf S, for the Collaborative Group on ACE Inhibitors Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. *JAMA*. 1995;273:1450-1456.
8. The AIRE study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet*. 1993;342:821-828.
9. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327:669-677.
10. Köber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliassen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. *N Engl J Med*. 1994;333:1670-1676.
11. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. *Lancet*. 1997;349(9064):1493-1497.
12. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med*. 1996;334:1349-1355.
13. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF) *Lancet*. 1999;353:2001-2007.
14. CIBIS-II Investigators and Committee. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet*. 1999;353:9-13.
15. Smith AJ, Wehner JS, Manley HJ, Richardson AD, Beal J, Bryant PJ. Current role of β -adrenergic blocker in the treatment of chronic congestive heart failure. *Am J Health-Syst Pharm*. 2001;58:140-145.

16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med.* 1999;341:709-717.
17. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, Lerebours G, Thuillez C. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin. *Circulation.* 2000;102:351-356.
18. Spargias KS, Lindsay SJ, Kawar GI, Greenwood DC, Cowan JC, Ball SG, Hall AS. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. *Eur Heart J.* 1999;20:1158-1165.
19. Spargias KS, Lindsay SJ, Hall AS, Cowan JC, Ball SG. Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure. *Am J Cardiol.* 1999;83(6):969-971.
20. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). *Nephrol Dial Transplant.* 1998;13:564-569.
21. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation.* 1999;100:2312-2318.
22. Massie BM, Armstrong PW, Cleland JG, Horowitz JD, Packer M, Poole-Wilson PA, Ryden L. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS Trial. *Arch Intern Med.* 2001;161:165-171.
23. Gombert-Maitland M, Baran DA, Fuster V. Treatment of congestive heart failure. Guidelines for the primary care physician and the heart failure specialist. *Arch Intern Med.* 2001;161:342-352.
24. Luzier AB, Forrest A, Feuerstein SG, Schentag JJ, Izzo JL. Containment of heart failure hospitalizations and cost by angiotensin-converting enzyme inhibitor dosage optimization. *Am J Cardiol.* 2000;86:519-523.
25. Grossman E, Messerli F. Angiotensin II receptor blockers: Equal or preferred substitutes for ACE inhibitors? *Arch Intern Med.* 2000;160:1905-1910.
26. Vaughan DE, Rouleau J-L, Ridker PM, Arnold MO, Menapace FJ, Pfeffer MA, on behalf of the HEART study investigators. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. *Circulation.* 1997;96:442-447.
27. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot study. *Circulation.* 1999;100:1056-1064.
28. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klingner GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. *Lancet.* 2000;355:1582-1587.
29. Pitt B, Segal R, Martinez F, Meurers G, Cowley AJ, Thomas I, Deedwania PC, New NE, Snively DB, Change PI. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet.* 1997;349:747-752.
30. Cohn JN, Tognoni G for the Val-HeFT Investigators. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Presented at the American Heart Association Scientific Sessions 2000,

November 15, 2000, New Orleans, La.

31. Jamali AH, Wilson WHW, Khot UN, Fowler MB. The role of angiotensin receptor blockers in the management of chronic heart failure. *Arch Intern Med.* 2001;161:667-672.
32. Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, Jondeau G, Olivari MT, Thomas S, Le Jemtel TH. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. *Circulation.* 1999;99:990-992.
33. Houghton AR, Harrison M, Perry AJ, Evans AJ, Cowley AJ. Combined treatment with losartan and angiotensin-converting enzyme inhibitor in chronic heart failure: a randomized, double-blind, placebo-controlled trial. *Eur Heart J.* 1998;19:302.
34. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
35. Guazzi M, Palermo P, Pontone G, Susini F, Agostoni P. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. *Am J Cardiol.* 1999;84:1038-1043.
36. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan. *Am J Cardiol.* 1999;83:477-481.
37. Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, Olofsson B, Ostergren J, Yusuf S. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. *J Card Fail.* 1999;5:276-282.
38. Pfeffer M, McMurray J, Leizorovicz A. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers. *Am Heart J.* 2000;139(suppl):S23-S28.